Skip to content

Cognitive Profiles in Early- and Late-Onset Alzheimer's Disease: The Role of Dementia Severity in Typical Amnestic Presentations Using the Addenbrooke's Cognitive Examination III.

Jul 2026 · Current Alzheimer Research · Vol 23 · 0 citations
Medicine

TL;DR

Cognitive performance reflects disease stage rather than age at onset, supporting the use of ACE-III for staging cognitive impairment rather than for differentiating EOAD from LOAD in typical amnestic presentations.

Abstract

INTRODUCTION Early-Onset (EOAD) and Late-Onset Alzheimer's Disease (LOAD) are often described as presenting distinct cognitive phenotypes. However, reported differences are inconsistent and may reflect demographic and severity-related confounding rather than stable etiological distinctions.

Materials And Methods

A retrospective analysis was conducted in 776 patients with clinically diagnosed Alzheimer's disease (EOAD, n = 175; LOAD, n = 601). Cognitive performance was assessed using the Addenbrooke's Cognitive Examination III (ACE-III) and the Mini-Mental State Examination (MMSE). Dementia severity was staged using the Functional Assessment Staging Tool (FAST). Cognitive outcomes were analysed using age- and severity-adjusted ANCOVA models including a diagnosis × age interaction. Severity-stratified and domain-level analyses were also performed.

Results

Unadjusted analyses revealed limited EOAD-LOAD differences in the Attention and Visuospatial domains, with small effect sizes. After adjustment for demographic variables and dementia severity, no cognitive measure reliably differentiated EOAD from LOAD. Cognitive performance showed similar cross-sectional patterns across groups and was primarily determined by dementia severity.

Discussion

Small, stage-dependent differences observed at mild and moderate stages did not persist in more advanced dementia and did not indicate stable cognitive dissociation between EOAD and LOAD.

Conclusions

After adjustment for demographic factors and dementia severity, EOAD and LOAD do not exhibit distinct cognitive profiles on ACE-III. Cognitive performance reflects disease stage rather than age at onset, supporting the use of ACE-III for staging cognitive impairment rather than for differentiating EOAD from LOAD in typical amnestic presentations.

View source

Similar papers

Open access Sep 2026

Multimodal network alterations in diagnosis-age-defined early- and late-onset Alzheimer’s disease

Introduction Early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD) may differ in large-scale network organization. We compared multimodal MRI markers of diagnosis-age-defined Alzheimer’s phenotypes. Methods Alzheimer’s Disease Neuroimaging Initiative participants were classified by age at fir...

Ze-Song Yuan, Jing Wang, Bao-Hua Cheng et al. · 0 citations
Open access Oct 2026

Comparative diagnostic accuracy and clinical utility of the Mini-Addenbrooke's Cognitive Examination, ACE-III, and MMSE for functional staging across the Alzheimer's disease continuum.

INTRODUCTION The advent of disease-modifying therapies has heightened the demand for cognitive screening instruments capable of detecting cognitive impairment and supporting both functional staging and longitudinal monitoring of Alzheimer's disease (AD). Although the Addenbrooke's Cognitive Examination III (ACE-III) of...

Anna Barczak, M. Golan, Beata Hintze · 0 citations
Open access Oct 2026

Cortical thickness signature of early-onset Alzheimer’s disease across clinical stages and A/T1 biomarker profiles

The cortical thinning signature of early-onset Alzheimer’s disease (EOAD) is well established in dementia, but its emergence during earlier disease stages remains unclear. We investigated when it becomes detectable and whether it differs according to fluid amyloid and phosphorylated-tau (A/T1) biomarker profiles. We st...

A. Zilioli, R. Mohanty, A. Rosenberg et al. · 0 citations
Sep 2026

Recognition memory as a neuropsychological marker of progression in early-stage Alzheimer's disease: a 24-month prospective cohort study.

SDT-derived recognition indices, especially d'prime, provide clinically relevant prognostic information in a-MCI and adding d' to delayed recall and biomarkers may improve risk stratification, follow-up planning, and selection for disease-modifying trials.

María Julieta Russo, José Bueri, L. Alba-Ferrara et al. · 0 citations
Aug 2026

Different hypothalamic regions in late-onset Alzheimer's disease and aging: involvement and links with cognitive and non-cognitive features.

This study provided a valuable insight into the heterogeneity of EOAD and LOAD, extending current understanding of the differential involvement of brain regions and highlighting the importance of hypothalamic involvement as a potential target for further investigation in conjunction with clinical assessment.

Giulia Quattrini, Martina Bocchetta, C. Bagattini et al. · 0 citations
Review Open access Sep 2026

Diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: Findings from an Italian real-world survey.

The real-world diagnostic journey, barriers, and management pathways of MCI and mild AD dementia patients in Italy is characterized to characterize the real-world diagnostic journey, barriers, and management pathways of biomarker-based diagnostics in Italy.

S. Ippati, Federico Torelli, Giovanna Zamboni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.